WFD Ventures

BionX Medical Technologies specializes in manufacturing advanced prosthetic devices aimed at enhancing the mobility and quality of life for individuals with amputations. The company's flagship product, the BiOM Ankle, features powered propulsion that allows for more natural movement by simulating human-like gait mechanics. This innovative prosthesis utilizes sophisticated microprocessors and environmental sensors to continuously assess and adjust its performance, providing users with the ability to navigate various terrains, including slopes and stairs, with reduced energy expenditure. BionX Medical Technologies serves its clientele through a network of prosthetists and healthcare providers, both in the United States and internationally. Founded in 2007 and headquartered in Bedford, Massachusetts, the company transitioned from its former name, iWalk, Inc., in 2015 and is currently a subsidiary of Otto Bock HealthCare GmbH.

OptiNose is a specialty pharmaceutical company focused on nasal drug delivery technologies and therapies for ear, nose, and throat conditions and related allergies. Its Exhalation Delivery System enables topically acting corticosteroids to reach the upper nasal cavity, supporting the commercial product XHANCE for chronic rhinosinusitis with and without nasal polyps. The company is advancing OPN-300 for Prader-Willi syndrome and autism spectrum disorder. It has licensing agreements for Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults and collaborates with Inexia Limited to develop orexin receptor targeting medicines. Founded in 2010 and based in Yardley, Pennsylvania, OptiNose aims to broaden nasal delivery with reproducible dosing and reduced systemic exposure.

Avisena, founded in 2001, is a healthcare technology company specializing in revenue cycle management. It provides a proprietary Internet-based solution designed to enhance collections, reduce costs, and improve operational efficiency for physician practices. By utilizing a physician management information system and advanced claims processing techniques, Avisena helps healthcare providers navigate the complexities of reimbursement driven by government regulations and fluctuating insurance payment rules. The company’s technology-based approach is gradually supplanting traditional in-house billing and medical billing companies, capturing a significant portion of the market. Clients typically experience a 10-20% improvement in collections compared to conventional methods. With a strong commitment to customer service and a retention rate of approximately 90%, Avisena employs 220 staff members and operates from a 26,000 square foot facility in Miami, Florida, with its technology infrastructure housed in a secure co-location facility.

OptiNose is a specialty pharmaceutical company focused on nasal drug delivery technologies and therapies for ear, nose, and throat conditions and related allergies. Its Exhalation Delivery System enables topically acting corticosteroids to reach the upper nasal cavity, supporting the commercial product XHANCE for chronic rhinosinusitis with and without nasal polyps. The company is advancing OPN-300 for Prader-Willi syndrome and autism spectrum disorder. It has licensing agreements for Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults and collaborates with Inexia Limited to develop orexin receptor targeting medicines. Founded in 2010 and based in Yardley, Pennsylvania, OptiNose aims to broaden nasal delivery with reproducible dosing and reduced systemic exposure.

BionX Medical Technologies specializes in manufacturing advanced prosthetic devices aimed at enhancing the mobility and quality of life for individuals with amputations. The company's flagship product, the BiOM Ankle, features powered propulsion that allows for more natural movement by simulating human-like gait mechanics. This innovative prosthesis utilizes sophisticated microprocessors and environmental sensors to continuously assess and adjust its performance, providing users with the ability to navigate various terrains, including slopes and stairs, with reduced energy expenditure. BionX Medical Technologies serves its clientele through a network of prosthetists and healthcare providers, both in the United States and internationally. Founded in 2007 and headquartered in Bedford, Massachusetts, the company transitioned from its former name, iWalk, Inc., in 2015 and is currently a subsidiary of Otto Bock HealthCare GmbH.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

OptiNose is a specialty pharmaceutical company focused on nasal drug delivery technologies and therapies for ear, nose, and throat conditions and related allergies. Its Exhalation Delivery System enables topically acting corticosteroids to reach the upper nasal cavity, supporting the commercial product XHANCE for chronic rhinosinusitis with and without nasal polyps. The company is advancing OPN-300 for Prader-Willi syndrome and autism spectrum disorder. It has licensing agreements for Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults and collaborates with Inexia Limited to develop orexin receptor targeting medicines. Founded in 2010 and based in Yardley, Pennsylvania, OptiNose aims to broaden nasal delivery with reproducible dosing and reduced systemic exposure.

BionX Medical Technologies specializes in manufacturing advanced prosthetic devices aimed at enhancing the mobility and quality of life for individuals with amputations. The company's flagship product, the BiOM Ankle, features powered propulsion that allows for more natural movement by simulating human-like gait mechanics. This innovative prosthesis utilizes sophisticated microprocessors and environmental sensors to continuously assess and adjust its performance, providing users with the ability to navigate various terrains, including slopes and stairs, with reduced energy expenditure. BionX Medical Technologies serves its clientele through a network of prosthetists and healthcare providers, both in the United States and internationally. Founded in 2007 and headquartered in Bedford, Massachusetts, the company transitioned from its former name, iWalk, Inc., in 2015 and is currently a subsidiary of Otto Bock HealthCare GmbH.

ImaCor is a company specializing in advanced medical devices for cardiac monitoring and management. It offers the ClariTEE probe and the Zura imaging system, which are designed to enhance hemodynamic management and provide high-quality echocardiography and transesophageal echocardiography. These devices enable clinicians to efficiently measure cardiac performance, improve patient outcomes, and optimize the use of healthcare resources. By facilitating direct cardiac visualization over time, ImaCor's technology supports healthcare professionals in making informed clinical decisions while also contributing to cost-effective resource utilization in hospital settings.

NanoPass Technologies Ltd. is a company focused on the development and commercialization of intradermal delivery solutions for vaccines and immunotherapies. Based in Nes Ziona, Israel, and founded in 2000, the company specializes in manufacturing hollow microneedles for intradermal injections and solid microprojections for cosmetic enhancement. Its flagship product, the MicronJet needle, is a single-use device designed for painless intradermal delivery. NanoPass collaborates with leading pharmaceutical companies and researchers to demonstrate the benefits of its technology across various medical applications. By pioneering virtually pain-free administration methods, the company aims to enhance patient care by facilitating the efficient delivery of drugs, proteins, and vaccines directly into the skin.